Capmatinib

1. Capmatinib - CAS 1029712-80-8 Capmatinib, also known as INCB28060 and INC280, is an orally bioavailable inhibitor of the proto-oncogene c-Met (hepatocyte growth factor receptor [HGFR]) with potential antineoplastic activity. It selectively binds to c-Met, thereby inhibiting c-Met phosphorylation and disrupting c-Met signal transduction pathways. This may induce cell death in tumor cells overexpressing c-Met protein or expressing constitutively activated c-Met protein. c-Met, a receptor tyrosine kinase overexpressed or mutated in many tumor cell types, plays key roles in tumor cell proliferation, survival, invasion, metastasis, and tumor angiogenesis. It has been granted Breakthrough Therapy Designation by FDA as a first-line treatment for patients with metastatic MET exon14 skipping-mutated non-small cell lung cancer (NSCLC). Please be kindly noted that our product can only be used for research to orgnizations or companies and we don't cooperate with personal buyers. Category Inhibitor Targets c-Met/HGFR SARS-CoV-2 Molecular Formula C23H17FN6O Molecular Weight 412.43 Chemical Information Category Inhibitor Molecular Formula C23H17FN6O Molecular Weight 412.43 Specification Properties  

2. Reference Reading  Appearance Yellow Solid Synonyms INCB28060; INC-280; INC280 Clinical Trial Information NCT Number Title Condition Or Disease Phase Start Date Sponsor Status NCT01324479Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors Solid Tumors Phase 1 February 29, 2012 Novartis Pharmaceuticals Completed NCT01546428A Phase I Study of INC280 in Japanese Patients With Advanced Solid Tumors Advanced Solid Tumor Phase 1 February 2012 Novartis Pharmaceuticals Completed NCT01610336A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET- amplified NSCLC Who Have Progressed After EGFRi Treatment Non-small Cell Lung Cancer Phase 2 April 5, 2012 Novartis Pharmaceuticals Active, not recruiting NCT01737827Study Efficacy and Safety of INC280 in Patients With Advanced Hepatocellular Carcinoma. Advanced Hepatocellular Carcinoma With c-MET Dysregulation Phase 2 March 25, 2013 Novartis Pharmaceuticals Active, not recruiting NCT01870726Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, Phase 2 January 9, 2014 Novartis Pharmaceuticals Terminated

3. INC280, BKM120, Buparlisib; Recurrent GBM Preparing Stock Solutions ConcentrationVolumeMass 1 mg 5 mg 10 mg 1 mM 2.4247 mL 12.1236 mL 24.2471 mL 5 mM - - - 10 mM - - - 50 mM - - - https://www.bocsci.com/capmatinib-cas-1029712-80-8-item-84-456525.html